Therapeutic Asset Ratings
435 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
TRASTUZUMAB
Sarcoma
OHSU Knight Cancer Institute
P1/2
CCC
(48)
Ipilimumab
Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
P1
CC
(47)
Olaparib
Estrogen-Receptor Negative Breast Cancer
OHSU Knight Cancer Institute
P1
CC
(47)
Olaparib
Progesterone-Receptor Negative Breast Cancer
OHSU Knight Cancer Institute
P1
CC
(47)
Zn-C3
Fallopian Tube Cancer
OHSU Knight Cancer Institute
P1/2
CC
(47)
Copanlisib
Plasma Cell Myeloma
OHSU Knight Cancer Institute
P2
CC
(46)
Entrectinib
Malignant Pancreatic Neoplasm
OHSU Knight Cancer Institute
P1
CC
(46)
Eribulin
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CC
(46)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Malignant Pancreatic Neoplasm
OHSU Knight Cancer Institute
P1
CC
(46)
(+)-VINCRISTINE
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CC
(46)
Zn-C3
Ovarian Carcinoma
OHSU Knight Cancer Institute
P1
CC
(46)
Axatilimab
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CC
(45)
Axatilimab
Recurrent Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CC
(45)
Axatilimab
Refractory Malignant Neoplasm
OHSU Knight Cancer Institute
P1/2
CC
(45)
Retifanlimab
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CC
(45)
Retifanlimab
Recurrent Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CC
(45)
Retifanlimab
Refractory Malignant Neoplasm
OHSU Knight Cancer Institute
P1/2
CC
(45)
Capecitabine
Refractory Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CC
(44)
Everolimus
Refractory Malignant Neoplasm
OHSU Knight Cancer Institute
P1
CC
(44)
Ipilimumab
Myeloproliferative Neoplasm
OHSU Knight Cancer Institute
P1
CC
(44)
Vinorelbine
Refractory Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CC
(44)
Entrectinib
Recurrent Acute Myeloid Leukemia
OHSU Knight Cancer Institute
P1
CC
(43)
ERIBULIN MONOMETHANESULFONATE
Liposarcoma
OHSU Knight Cancer Institute
P1
CC
(43)
ERIBULIN MONOMETHANESULFONATE
Malignant Abdominal Neoplasm
OHSU Knight Cancer Institute
P1
CC
(43)
ERIBULIN MONOMETHANESULFONATE
Retroperitoneal Cancer
OHSU Knight Cancer Institute
P1
CC
(43)
Showing 301 to 325 of 435 assets
Previous
Page 13 of 18
Next
